INTERCEPT‐AD: A Gender Analysis of the Phase 1 Experience Among Trial Participants with Early Alzheimer’s Disease and Their Study Partners
Kelly Johnston, Carrie Presnall, Elizabeth Merikle, Stephanie Cline, Robyn Moxon, Todd Feaster, Eric Siemers · 2025
Read INTERCEPT‐AD: A Gender Analysis of the Phase 1 Experience Among Trial Participants with Early Alzheimer’s Disease and Their Study Partners by Kelly Johnston, Carrie Presnall, Elizabeth Merikle, Stephanie Cline, Robyn Moxon, Todd Feaster, Eric Siemers (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716791.txt.
Description
Kelly Johnston and six co-authors published a study in 2025 on what men and women experienced inside an early Alzheimer's drug trial. The trial tested an antibody aimed at a toxic form of amyloid. Alongside it, researchers interviewed patients with early disease and their study partners about joining and taking part.
Interviews covered how people heard about the trial, why they joined, and what worried or pleased them. The team sorted each pair by the patient's gender and compared the themes that came up. Clear gaps between men's and women's accounts appeared on several topics. Drug developers can use such feedback to design trials that keep more volunteers enrolled and informed.
Catalog record
| CREATOR | Kelly Johnston, Carrie Presnall, Elizabeth Merikle, Stephanie Cline, Robyn Moxon, Todd Feaster, Eric Siemers |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |